Co-Authors
This is a "connection" page, showing publications co-authored by Lorenzo Piemonti and Fabio Ciceri.
Connection Strength
1.616
-
Thromboembolism risk among patients with diabetes/stress hyperglycemia and COVID-19. Metabolism. 2021 10; 123:154845.
Score: 0.240
-
Pre-Existing Diabetes and COVID-Associated Hyperglycaemia in Patients with COVID-19 Pneumonia. Biology (Basel). 2021 Aug 05; 10(8).
Score: 0.240
-
Dysglycemia after COVID-19 pneumonia: a six-month cohort study. Acta Diabetol. 2021 Nov; 58(11):1481-1490.
Score: 0.237
-
Robust Neutralizing Antibodies to SARS-CoV-2 Develop and Persist in Subjects with Diabetes and COVID-19 Pneumonia. J Clin Endocrinol Metab. 2021 04 23; 106(5):1472-1481.
Score: 0.235
-
Antibody response to multiple antigens of SARS-CoV-2 in patients with diabetes: an observational cohort study. Diabetologia. 2020 12; 63(12):2548-2558.
Score: 0.227
-
Islet Allotransplantation in the Bone Marrow of Patients With Type 1 Diabetes: A Pilot Randomized Trial. Transplantation. 2019 04; 103(4):839-851.
Score: 0.204
-
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 2021 08 19; 6(62).
Score: 0.060
-
Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. Nat Commun. 2021 05 11; 12(1):2670.
Score: 0.059
-
COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain. J Clin Invest. 2020 12 01; 130(12):6366-6378.
Score: 0.057
-
Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020 10 23; 370(6515).
Score: 0.057